BMO maintains Novo Nordisk stock target post FDA nod
BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...
How to Play NVO Stock After New Drug's Success in Obesity Study
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...
Outsourcing-pharma15h
Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Investing15h
Novo Nordisk: Lasting Correction or Opportunity?
Since the Novo Nordisk (CSE: NOVOb) share price peaked in June last year just above the DKK 1,000 mark, it has suffered a severe setback and has now fallen by over 40%. In Decembe ...
Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
UBS Remains a Buy on Novo Nordisk (0QIU)
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
PipelineReview.com23h
Herantis Pharma: encouraging pharmacokinetic data and first subject with Parkinson’s disease dosed in the Phase 1b trial
I Herantis Pharma Plc ("Herantis"), a company developing disease-modifying therapies for Parkinson’s disease, is pleased to announce an ...